CME : 0.5
Ketamine for Treatment-Resistant Depression is organized by The American Psychiatric Association (APA).
Start Date : Jan 01, 2018
End Date: Dec 31, 2020
This Course has been Approved for a maximum of 0.5 AMA PRA Category 1 Credits.
This presentation reviews, in detail, the results of randomized trials of intravenous or intranasal ketamine for treatment-resistant unipolar and bipolar major depression, highlighting methodological limitations of the most important studies and limitations of study findings for long-term ketamine administration. The presenter is a clinician familiar with the use of intravenous ketamine in acute settings at a major academic medical center.
• Describe the key findings from the most important studies of the effectiveness and safety of low-dose ketamine for the acute management of treatment-resistant unipolar or bipolar major depression.
• Define the principal short- and long-term safety and tolerability concerns regarding the use of low-dose ketamine for the management of treatment-resistant unipolar or bipolar major depression.
• Discuss the methods applied at Mayo Clinic and clinical programming steps that have been undertaken in order to develop a ketamine infusion therapy service.
This course is currently offered as a free member benefit through the Course of the Month program. Promotional pricing valid from January 1-31, 2018.
|Registration Type||Due Date||Price|
|Course Fee||30 Dec,2020||Free|
- 60 Minutes
- 30 Minutes
- 60 Minutes
Browse Online CME / CE Conferences by Specialty View All
- Clinical Pharmacology
- Emergency Medicine
- Endocrinology, Metabolism and Diabetes
- Healthcare Management
- Immunology and Microbiology
- Infectious Disease
- Medical Education
- Obstetrics and Gynecology
- Pain Management
- Pharmacy and Medicine
- Primary Care
- Pulmonary Medicine